Dry Age-Related Macular Degeneration Market: Market Share and Revenue Analysis 2024-2032
The global Dry Age-Related Macular Degeneration (AMD) market, valued at $4.83 billion in 2023, is projected to surge to $10.57 billion by 2032, exhibiting a robust Compound Annual Growth Rate (CAGR) of 9.1% during the forecast period from 2024 to 2032.
Market Overview
Dry Age-Related Macular Degeneration is a prevalent ocular condition, particularly among the elderly, leading to progressive vision loss. The escalating incidence of AMD, especially within aging populations, underscores the critical need for effective treatments and interventions.
Get free sample report @ https://www.snsinsider.com/sample-request/2627
Regional Analysis
- North America: Dominates the market due to a significant elderly demographic and advanced healthcare infrastructure.
- Europe: Exhibits substantial growth driven by increased awareness and proactive healthcare policies.
- Asia-Pacific: Anticipated to witness the fastest growth, attributed to a burgeoning aging population and improving healthcare facilities.
Market Segmentation
The Dry AMD market is segmented based on:
- Stages: Intermediate and Late Age-Related Macular Degeneration.
- Age Group: Categorized by specific age brackets to tailor treatment approaches.
- Diagnosis and Treatment: Encompasses various diagnostic tools and therapeutic interventions.
- Route of Administration: Includes intravitreal injections, oral medications, and other delivery methods.
- End User: Targets hospitals, clinics, and specialized ophthalmic centers.
Key Players in the Dry Age-Related Macular Degeneration Market
Treatment Providers
- Bayer AG
- Pfizer Inc.
- Amgen Inc.
- Biogen
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Samsung Bioepis
- Bausch Health Companies Inc.
- Regeneron Pharmaceuticals Inc.
- Santen Pharmaceuticals Inc.
- Allergan plc
- Alimera Sciences Inc.
- Phio Pharmaceuticals Corp
- Iveric Bio
- Belite Bio Inc.
Diagnosis Providers
- Bausch Health Companies Inc.
- Alimera Sciences Inc.
- Ocumension Therapeutics Co. Ltd
- Iveric Bio
Device Manufacturers
- Bausch Health Companies Inc.
- Regeneron Pharmaceuticals Inc.
- Biogen
- Eyestem Research Pvt Ltd
- Kubota Vision Inc.
Key Market Drivers
- Aging Population: The global increase in the elderly population significantly raises the prevalence of Dry AMD.
- Lifestyle Factors: Habits such as smoking, alcohol consumption, and physical inactivity contribute to the disease's onset.
- Advancements in R&D: Continuous research efforts are leading to the development of innovative treatment modalities.
- Improved Reimbursement Policies: Enhanced insurance coverage facilitates better access to AMD therapies.
Future Outlook
The Dry Age-Related Macular Degeneration market is on a trajectory of significant expansion, propelled by demographic shifts and lifestyle influences. The focus on research and development is expected to yield novel therapeutic options, addressing unmet medical needs and improving patient outcomes. Emerging markets present lucrative opportunities, with healthcare infrastructure advancements and increased awareness contributing to market penetration.
Conclusion
The projected growth of the Dry Age-Related Macular Degeneration market reflects a confluence of factors, including an aging global population, lifestyle-related risk factors, and strides in medical research. Stakeholders in the healthcare sector are poised to benefit from these trends, with a concerted effort towards innovation and accessibility in AMD treatment solutions.
Contact Us:
Jagney Dave - Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Other Related Reports:
English
Arabic
Français
Español
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian